Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.

This publication has 137 references indexed in Scilit: